The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored
Iverzine Dosage
Applies to the following strength(s): 3 mg; 6 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Onchocerciasis
Strongyloidiasis
Ascariasis
Cutaneous Larva Migrans
Filariasis
Scabies
Usual Pediatric Dose for:
Filariasis
Additional dosage information:
Renal Dose Adjustments
Liver Dose Adjustments
Dose Adjustments
Precautions
Dialysis
Other Comments
Usual Adult Dose for Onchocerciasis
0.15 mg/kg orally once every 12 months
Patients with heavy ocular infection may require retreatment every 6 months. Retreatment may be considered at intervals as short as 3 months.
Dosage guidelines based on body weight:
15 to 25 kg: 3 mg orally one time
26 to 44 kg: 6 mg orally one time
45 to 64 kg: 9 mg orally one time
65 to 84 kg: 12 mg orally one time
85 kg or more: 0.15 mg/kg orally one time
Usual Adult Dose for Strongyloidiasis
0.2 mg/kg orally once
In immunocompromised (including HIV) patients, the treatment of strongyloidiasis may be refractory requiring repeated treatment (i.e., every 2 weeks) and suppressive therapy (i.e., once a month), although well-controlled studies are not available. Cure may not be achievable in these patients.
Dosage guidelines based on body weight:
15 to 24 kg: 3 mg orally one time
25 to 35 kg: 6 mg orally one time
36 to 50 kg: 9 mg orally one time
51 to 65 kg: 12 mg orally one time
66 to 79 kg: 15 mg orally one time
80 kg or more: 0.2 mg/kg orally one time
Usual Adult Dose for Ascariasis
0.2 mg/kg orally once
Usual Adult Dose for Cutaneous Larva Migrans
0.2 mg/kg orally once
Usual Adult Dose for Filariasis
0.2 mg/kg orally once
Study (n=26,000)
Mass treatment in Papua, New Guinea:
Bancroftian filariasis: 0.4 mg/kg orally once yearly (with a single annual dose of diethylcarbamazine 6 mg/kg), for 4 to 6 years
Usual Adult Dose for Scabies
0.2 mg/kg orally once, and repeated in 2 weeks
Iverzine therapy may be combined with a topical scabicide.
Usual Pediatric Dose for Filariasis
Study (n=26,000)
Mass treatment in Papua, New Guinea:
Bancroftian filariasis:
5 years or older: 0.4 mg/kg orally once yearly (with a single annual dose of diethylcarbamazine 6 mg/kg), for 4 to 6 years
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
Retreatment is required because Iverzine has no activity against adult onchocerca volvulus parasites which tend to reside in subcutaneous nodules. Surgical excision of these nodules may be considered to eliminate the adult reproduction of microfilariae.
Patients with crusted scabies may require two or more doses of Iverzine spaced at one to two week intervals.
Precautions
Cutaneous, systemic and/or ophthalmological reactions have been reported with other microfilaricidal drugs. Allergic and inflammatory reactions (the Mazzotti reaction) may occur with Iverzine, probably due to the death of the microfilariae. Patients treated with Iverzine therapy for onchocerciasis may experience these reactions in addition to clinical adverse reactions possibly, probably, or definitely related to the therapy itself. The treatment of severe Mazzotti reactions has not been subjected to controlled clinical studies.
Oral or intravenous rehydration, corticosteroids, antihistamines, acetaminophen and/or aspirin have been used for treatment.
After treatment with microfilaricidal medications, patients with hyperreactive onchodermatitis (sowda) may be more likely than others to experience severe adverse reactions, especially edema and aggravation of onchodermatitis.
Serious or fatal encephalopathy has been reported rarely in patients with onchocerciasis, and heavily infected with Loa loa, either spontaneously or after treatment with Iverzine. In these patients, pain (including neck and back pain), red eye, conjunctival hemorrhage, dyspnea, urinary and/or fecal incontinence, difficulty in standing/walking, mental status changes, confusion, lethargy, stupor, seizures, or coma have been reported. This syndrome has been seen very rarely following the use of Iverzine therapy. Pretreatment assessment for loiasis and careful posttreatment follow-up should be implemented in all patients considered for treatment with Iverzine for any reason and who had exposure to Loa loa endemic areas of West and Central Africa.
The patient should be advised of the need for repeated stool examinations to document clearance of infection with Strongyloides stercoralis.
The patient should be advised that treatment with Iverzine does not kill the adult Onchocerca parasites, and therefore repeated follow-up and retreatment is usually necessary.
In immunocompromised (including HIV-infected) patients being treated for intestinal strongyloidiasis, repeated courses of therapy may be necessary. Adequate and well-controlled clinical trials have not been conducted in such patients to determine the optimal dosing regimen. Several treatments, i.e., at 2-week intervals, may be required, and cure may not be attained. Control of extraintestinal strongyloidiasis in these patients is difficult, and suppressive therapy, i.e., once per month, may be useful.
Iverzine is extensively metabolized in the liver and should be used cautiously in patients with hepatic disease. Dosage adjustments may be needed, although specific recommendations are not currently available. The manufacturer does not recommend that Iverzine treatment be excluded in patients with liver disease.
Clinical trials of Iverzine did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, treatment of elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Safety and effectiveness in pediatric patients weighing less than 15 kg have not been determined.
Dialysis
Data not available
Other Comments
Each Iverzine dose should be taken on an empty stomach with a full (8 oz) glass of water.
A recent pharmacokinetics study reports that following a high-fat meal absorption was significantly higher (about 2.5 times) than in the fasted state.
More about Iverzine
Side Effects
During Pregnancy or Breastfeeding
Dosage Information
Drug Interactions
Support Group
Pricing & Coupons
En Espanol
4 Reviews - Add your own review/rating
Consumer resources
Iverzine
Iverzine (Advanced Reading)
Other brands: Stromectol
Professional resources
Iverzine (AHFS Monograph)
More (2) »
Related treatment guides
Cutaneous Larva Migrans
Scabies
Head Lice
Ascariasis
Filariasis, Elephantiasis
More (2) »
What other drugs will affect Iverzine?
Other drugs may interact with Iverzine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
See also:
Iverzine drug interactions (in more detail)
Iverzine interactions
Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Iverzine, it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored
Azithromycin (Systemic): May increase the serum concentration of Iverzine (Systemic). Monitor therapy
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Avoid combination
Lumacaftor and Ivacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor and Ivacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy
P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy
P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Monitor therapy
Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Iverzine (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Monitor therapy
sponsored
Reviews
The results of a survey conducted on ndrugs.com for Iverzine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Iverzine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
1 consumer reported frequency of use
How frequently do I need to take Iverzine? It was reported by ndrugs.com website users that Iverzine should ideally be taken Twice in a day as the most common frequency of the Iverzine. You should you adhere strictly to the instructions and guidelines provided by your doctor on how frequently this Iverzine should be taken. Get another patient's view on how frequent the capsule should be used by clicking here.
Users
%
Twice in a day
1
100.0%
6 consumers reported doses
What doses of Iverzine drug you have used? The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Iverzine drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
